Insights

Strategic Partnership Brazilian biotech Bionovis actively engages in joint production and development with BahiaFarma and Biocon Biologics for Pertuzumab, signaling a clear pathway for regionalized supply, technology transfer, and long-term public sector contracts that sales teams can target.

Public Sector Focus Recent announcements emphasize Brazil's public healthcare market access through a 10-year Productive Development Partnership program, suggesting steady government-led procurement opportunities for biosimilars and innovative biologics.

Pipeline opportunity Bionovis plans a diversified pipeline including biosimilars, biobetters, and innovative biologics, creating multiple selling points across monoclonal antibodies and therapeutic proteins for hospital systems, distributors, and public tenders.

Global Collaboration Strategic partnerships with international leaders and public institutions indicate strong credibility and potential for co-development deals, licensing, and access to global best practices that can be leveraged in sales pitches.

Financial Growth Signals Current revenue is under one million with a high-growth, long-term government program enabling phased production localization; sales teams can emphasize scalable manufacturing capabilities and local content to win public contracts and regional pharma partnerships.

Similar companies to Bionovis

Bionovis Tech Stack

Bionovis uses 8 technology products and services including LinkedIn Ads, Power BI, AutoCAD, and more. Explore Bionovis's tech stack below.

Media & News

Bionovis's Email Address Formats

Bionovis uses at least 3 email formats:
Bionovis Email FormatsExamplePercentage
First.Last@bionovis.com.brJohn.Doe@bionovis.com.br
98%
First-Last@bionovis.com.brJohn-Doe@bionovis.com.br
1%
First.Middle@bionovis.com.brJohn.Michael@bionovis.com.br
1%

Frequently Asked Questions

What is Bionovis's official website and social media links?

Minus sign iconPlus sign icon
Bionovis's official website is bionovis.com.br and has social profiles on LinkedIn.

How much revenue does Bionovis generate?

Minus sign iconPlus sign icon
As of October 2026, Bionovis's annual revenue is estimated to be <$1M.

What is Bionovis's SIC code and NAICS code?

Minus sign iconPlus sign icon
Bionovis's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Bionovis have currently?

Minus sign iconPlus sign icon
As of October 2026, Bionovis has approximately 338 employees across 2 continents, including South America and Europe. Key team members include Chief Executive Officer: O. F., Ceo: O. F. and Chief Scientific Officer: V. R. Explore Bionovis's employee directory with LeadIQ.

What industry does Bionovis belong to?

Minus sign iconPlus sign icon
Bionovis operates in the Biotechnology Research industry.

What technology does Bionovis use?

Minus sign iconPlus sign icon
Bionovis's tech stack includes LinkedIn Ads, Power BI, AutoCAD, Amazon Web Services, WordPress, Firebase, Microsoft 365 and Adobe Creative Suite.

What is Bionovis's email format?

Minus sign iconPlus sign icon
Bionovis's email format typically follows the pattern of First.Last@bionovis.com.br. Find more Bionovis email formats with LeadIQ.

When was Bionovis founded?

Minus sign iconPlus sign icon
Bionovis was founded in 2012.
Bionovis logo

Bionovis

Biotechnology ResearchSão Paulo, Brazil201-500 Employees

Bionovis is a 100% Brazilian biotechnology company focused on researching, developing, manufacturing, and commercializing complex biopharmaceuticals of high quality to improve patient outcomes. Situated in the evolving global biopharmaceutical landscape, the company is advancing production of highly complex biological medicines in Brazil. Its development plan includes a pipeline of biosimilars, biobetters, and innovative biopharmaceuticals, supported by capabilities to produce monoclonal antibodies and therapeutic proteins. Its activities are supported by collaborations with global industry leaders and with major national public institutions, aligning its efforts with public health needs. Headquartered in Valinhos, in the São Paulo region, Bionovis is described as a mid-sized enterprise with substantial infrastructure and expertise. In February 2026, the company announced a commitment to the productive development of Pertuzumab, a treatment for HER-2 positive metastatic breast cancer, aimed at serving an estimated 72,000 patients annually.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2012
Employees
201-500

Section iconFunding & Financials

  • <$1M

    Bionovis's revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.